



Ken W. Cole
Vice President
Government Relations
Public Policy Center

General Motors Corporation
25 Massachusetts Avenue, N.W.
Suite 400
Washington, D.C. 20001
Tel 202-775-5090
Fax 202-775-5023

February 14, 2007

The Honorable Henry A. Waxman
Chairman, Committee on Oversight and Government Reform
United States House of Representatives
Washington, D.C. 20515

Dear Mr. Chairman:

On behalf of General Motors Corporation, I am writing to endorse the "Access to Life Saving Medicine Act of 2007." This legislation would provide a clear and definitive pathway at the Food and Drug Administration for the approval of safe and effective biogenerics. The legislation appropriately gives full discretion to the FDA to use its scientific expertise to determine the safety and efficacy of biogenerics, an approach which will increase the accessibility and affordability of these life-saving medicines to millions of Americans.

As the largest private purchaser of health care in the United States, GM is committed to improving access to safe, affordable pharmaceuticals for our 1.1 million employees, retirees, and their families. As an automobile company, GM is also a leader in safety and innovation. We support this legislation because it ensures patient safety while striking the right balance between incentives for innovation and promoting competition in the pharmaceutical market.

General Motors commends you for your leadership and bipartisan efforts to craft this important legislation. We look forward to working with you and others to improve access to safe, affordable, and effective biogenerics.

Sincerely,